FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2287338484> ?p ?o ?g. }

• W2287338484 endingPage "e0149030" @default.
• W2287338484 startingPage "e0149030" @default.
• W2287338484 abstract "Importance The fellow eye of patients with unilateral neovascular age-related degeneration (nAMD) is at increased risk of developing late AMD. Several cohort studies have evaluated the prevalence of pseudodrusen and the association between pseudodrusen and late AMD in the fellow eye of patients with unilateral nAMD. However, these studies have limited sample sizes and their results are inconsistent. Objective To evaluate the prevalence rate of pseudodrusen, and the association between pseudodrusen and incidence of late AMD (nAMD and geographic atrophy (GA)) in the fellow eye of patients with unilateral nAMD. Data Sources The PubMed, EMBASE, Web of Science, and Cochrane Library databases were searched up to July 2015, as well as other systematic reviews. Study Selection All cohort studies for pseudodrusen with late AMD in the fellow eye of patients with unilateral nAMD. Data Extraction and Synthesis The numbers of patients with and without pseudodrusen at baseline and the numbers of incident nAMD and GA during follow up among patients with and without pseudodrusen were independently extracted by 2 authors. The results were pooled using random-effects meta-analysis. Heterogeneity was assessed using the I2 test. Main Outcome Measures Prevalence rate of pseudodrusen, risk ratios (RRs) and their 95% confidence intervals (95% CIs) for associations between pseudodrusen and the incidence of nAMD and GA in the fellow eye. Results Five cohort studies (N = 677 patients) from 8 countries across 4 continents were included. The pooled prevalence rate of pseudodrusen in the fellow eye was 48.1% (95% Cl: 36.7–59.5%, I2 = 87%). Pseudodrusen were associated with an increased risk of nAMD (RR = 1.54, 95% Cl: 1.10–2.16, I2 = 42%), GA (RR = 4.70, 95% Cl: 1.22–18.1, I2 = 64%), and late AMD (RR = 2.03, 95% Cl: 1.35–3.06, I2 = 60%). Conclusions For patients with unilateral nAMD, pseudodrusen were present in about half of the fellow eyes. The presence of pseudodrusen was associated with a 1.5 times higher risk of developing nAMD, a 4.7 times higher risk of developing GA, and a 2 times higher risk of developing late AMD. Pseudodrusen should be considered in evaluating the risk of late AMD development; however, due to considerable heterogeneity across these studies, a larger study is needed to validate these findings." @default.
• W2287338484 created "2016-06-24" @default.
• W2287338484 creator A5065295070 @default.
• W2287338484 creator A5075836236 @default.
• W2287338484 creator A5091037202 @default.
• W2287338484 date "2016-02-19" @default.
• W2287338484 modified "2023-09-28" @default.
• W2287338484 title "Pseudodrusen in the Fellow Eye of Patients with Unilateral Neovascular Age-Related Macular Degeneration: A Meta-Analysis" @default.
• W2287338484 cites W1543801259 @default.
• W2287338484 cites W1696340081 @default.
• W2287338484 cites W1805219048 @default.
• W2287338484 cites W183193446 @default.
• W2287338484 cites W1965478508 @default.
• W2287338484 cites W1970099649 @default.
• W2287338484 cites W1979423827 @default.
• W2287338484 cites W1980751081 @default.
• W2287338484 cites W1980954887 @default.
• W2287338484 cites W1988962811 @default.
• W2287338484 cites W1990638682 @default.
• W2287338484 cites W1998513268 @default.
• W2287338484 cites W2011845506 @default.
• W2287338484 cites W2023886778 @default.
• W2287338484 cites W2028982261 @default.
• W2287338484 cites W2045011938 @default.
• W2287338484 cites W2049032499 @default.
• W2287338484 cites W2049962938 @default.
• W2287338484 cites W2054899217 @default.
• W2287338484 cites W2058944176 @default.
• W2287338484 cites W2065895674 @default.
• W2287338484 cites W2074877793 @default.
• W2287338484 cites W2076103048 @default.
• W2287338484 cites W2078466179 @default.
• W2287338484 cites W2084190964 @default.
• W2287338484 cites W2084438553 @default.
• W2287338484 cites W2086134192 @default.
• W2287338484 cites W2090949500 @default.
• W2287338484 cites W2092589500 @default.
• W2287338484 cites W2101893462 @default.
• W2287338484 cites W2106225209 @default.
• W2287338484 cites W2111379072 @default.
• W2287338484 cites W2113924557 @default.
• W2287338484 cites W2126930838 @default.
• W2287338484 cites W2134977179 @default.
• W2287338484 cites W2156616469 @default.
• W2287338484 cites W2171855270 @default.
• W2287338484 cites W2315867955 @default.
• W2287338484 cites W2331995156 @default.
• W2287338484 cites W2333335636 @default.
• W2287338484 cites W4239144248 @default.
• W2287338484 cites W4240524385 @default.
• W2287338484 cites W4247214019 @default.
• W2287338484 cites W4321509030 @default.
• W2287338484 cites W95909858 @default.
• W2287338484 doi "https://doi.org/10.1371/journal.pone.0149030" @default.
• W2287338484 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4760707" @default.
• W2287338484 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26895455" @default.
• W2287338484 hasPublicationYear "2016" @default.
• W2287338484 type Work @default.
• W2287338484 sameAs 2287338484 @default.
• W2287338484 citedByCount "7" @default.
• W2287338484 countsByYear W22873384842017 @default.
• W2287338484 countsByYear W22873384842018 @default.
• W2287338484 countsByYear W22873384842019 @default.
• W2287338484 countsByYear W22873384842022 @default.
• W2287338484 countsByYear W22873384842023 @default.
• W2287338484 crossrefType "journal-article" @default.
• W2287338484 hasAuthorship W2287338484A5065295070 @default.
• W2287338484 hasAuthorship W2287338484A5075836236 @default.
• W2287338484 hasAuthorship W2287338484A5091037202 @default.
• W2287338484 hasBestOaLocation W22873384841 @default.
• W2287338484 hasConcept C118487528 @default.
• W2287338484 hasConcept C120665830 @default.
• W2287338484 hasConcept C121332964 @default.
• W2287338484 hasConcept C126322002 @default.
• W2287338484 hasConcept C201903717 @default.
• W2287338484 hasConcept C2776403814 @default.
• W2287338484 hasConcept C44249647 @default.
• W2287338484 hasConcept C61511704 @default.
• W2287338484 hasConcept C71924100 @default.
• W2287338484 hasConcept C72563966 @default.
• W2287338484 hasConcept C95190672 @default.
• W2287338484 hasConceptScore W2287338484C118487528 @default.
• W2287338484 hasConceptScore W2287338484C120665830 @default.
• W2287338484 hasConceptScore W2287338484C121332964 @default.
• W2287338484 hasConceptScore W2287338484C126322002 @default.
• W2287338484 hasConceptScore W2287338484C201903717 @default.
• W2287338484 hasConceptScore W2287338484C2776403814 @default.
• W2287338484 hasConceptScore W2287338484C44249647 @default.
• W2287338484 hasConceptScore W2287338484C61511704 @default.
• W2287338484 hasConceptScore W2287338484C71924100 @default.
• W2287338484 hasConceptScore W2287338484C72563966 @default.
• W2287338484 hasConceptScore W2287338484C95190672 @default.
• W2287338484 hasIssue "2" @default.
• W2287338484 hasLocation W22873384841 @default.
• W2287338484 hasLocation W22873384842 @default.
• W2287338484 hasLocation W22873384843 @default.
• W2287338484 hasLocation W22873384844 @default.
• W2287338484 hasOpenAccess W2287338484 @default.

• next